Financiële vergelijkingen Haw Par Corporation Limited
Aandelen
H02
SG1D25001158
Farmaceutische producten
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
10,74 SGD | +1,42% | +2,58% | +10,15% |
15/08 | Haw Par's winst stijgt met 16% in H1 | MT |
14/08 | Haw Par Corporation Limited rapporteert resultaten voor het halfjaar dat eindigde op 30 juni 2024 | CI |
Toevoegen aan een lijst 0 geselecteerde | Omzet ($) (Y-1) | Nettomarge (Y-1) | Bedrijfsmarge (Y-1) | ROE (Y-1) | ROA (Y-1) | Hefboom (schuld/EBITDA) (Y-1) | |
---|---|---|---|---|---|---|---|
5,78 mld. | +19.75% | +20.56% | +16.00% | +11.52% | -1.3x | ||
14,12 mld. | +6.02% | +6.92% | +5.30% | +4.41% | -1.58x | ||
9,65 mld. | +0.80% | +15.42% | +10.96% | +5.15% | 1.79x | ||
3,07 mld. | +15.99% | +20.33% | +16.45% | +13.26% | -0.86x | ||
2,33 mld. | +19.74% | +23.64% | +20.61% | +13.98% | -0.06x | ||
3,52 mld. | +25.46% | +31.82% | +16.70% | +18.23% | -0.93x | ||
1,41 mld. | -12.71% | +5.19% | -11.52% | - | -0.56x | ||
2,24 mld. | +19.73% | +23.58% | +14.48% | +11.70% | -0.33x | ||
501 mln. | +19.39% | +24.63% | +23.47% | - | -0.68x | ||
2,27 mld. | +12.84% | +19.21% | +6.65% | +4.26% | 1.65x | ||
473 mln. | +17.24% | +19.49% | +7.35% | +6.06% | -1.25x | ||
1,99 mld. | +17.38% | +22.12% | +14.50% | +11.50% | -0.35x | ||
293 mln. | +26.56% | +28.47% | +22.32% | +19.10% | -0.83x | ||
762 mln. | +16.63% | +18.59% | +23.90% | +12.19% | - | ||
1,11 mld. | +10.68% | +14.80% | +15.15% | +7.65% | 1.59x | ||
Gemiddelde | 3,3 mld. | +14,37% | +19,65% | +13,49% | +10,69% | -0,26x | |
Gewogen gemiddelde per kap. | 6,02 mld. | +13,83% | +17,99% | +13,03% | +9,87% | -0,64x |
- Beurs
- Aandelen
- Koers H02
- Sector Haw Par Corporation Limited
- Financiële vergelijkingen